Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of “Reduce” by Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have received a consensus recommendation of “Reduce” from the eighteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $36.60.

MRNA has been the subject of a number of research reports. Sanford C. Bernstein reiterated a “market perform” rating and set a $45.00 target price on shares of Moderna in a research report on Tuesday, February 17th. Bank of America increased their target price on Moderna from $32.00 to $34.00 and gave the company an “underperform” rating in a research report on Monday, June 8th. The Goldman Sachs Group increased their target price on Moderna from $43.00 to $49.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Evercore set a $35.00 target price on Moderna in a research report on Tuesday, February 17th. Finally, Piper Sandler increased their target price on Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a research report on Monday, February 23rd.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $46.84, for a total value of $433,878.92. Following the sale, the director owned 3,924 shares in the company, valued at $183,800.16. The trade was a 70.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 71,752 shares of company stock valued at $3,453,843 over the last quarter. 10.80% of the stock is owned by insiders.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently bought and sold shares of the stock. MUFG Securities EMEA plc purchased a new stake in Moderna during the 2nd quarter valued at $28,000. Flagship Harbor Advisors LLC purchased a new stake in Moderna during the 4th quarter valued at $31,000. Canton Hathaway LLC purchased a new stake in Moderna during the 1st quarter valued at $31,000. Ameriflex Group Inc. raised its holdings in Moderna by 3,775.0% during the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after buying an additional 1,208 shares during the period. Finally, Cromwell Holdings LLC raised its holdings in Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after buying an additional 341 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 4.4%

NASDAQ MRNA opened at $52.13 on Tuesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. The company has a market capitalization of $20.68 billion, a P/E ratio of -6.40 and a beta of 1.05. Moderna has a one year low of $22.28 and a one year high of $59.55. The stock has a 50 day moving average price of $49.67 and a 200-day moving average price of $44.36.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm’s revenue was up 260.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.52) earnings per share. As a group, equities analysts predict that Moderna will post -6.51 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.